These 25 options into established treatments, alternatives used in selected circumstances, laboratory-stage compounds, and other proposed options. That distinction matters because an intervention that kills Babesia in a laboratory is not necessarily effective or safe in a human patient.
Important clinical distinction: Severe babesiosis can cause hemolytic anemia, renal failure, respiratory failure, shock, and death. Evidence-supported antimicrobial treatment and, in selected severe cases, red-cell exchange transfusion take priority over experimental procedures. HBOT, SOT, and EBOO are not established Babesia-eradicating treatments. Though in our human research we have seen Babesia numbers lowered with EBOO.
1. Evidence-Supported Pharmaceuticals and Medical Interventions
Evidence level: Established clinical use unless otherwise indicated.
| # | Treatment | Rationale and Evidence |
|---|---|---|
| 1 | Atovaquone + azithromycin | Preferred regimen for most symptomatic patients with uncomplicated babesiosis. Acts against different parasite targets. Human clinical evidence. [1,2]. Our 2009 Babesia Update Book shares results on human cure. The common low dose of both was not effective in humans. |
| 2 | Clindamycin + quinine | Established alternative regimen; often used in severe disease when clinically appropriate. Quinine can cause substantial adverse effects, including QT prolongation, hypoglycemia, and cinchonism. [1,2] |
| 3 | Intravenous azithromycin + atovaquone | For selected hospitalized patients with severe disease, IV azithromycin may be used initially, with oral atovaquone when feasible. [1,2] My bias is to use both if possible. |
| 4 | Atovaquone + azithromycin + clindamycin | A specialist-directed combination [Specialist means? Someone who studied Babesia for 15 minutes?] sometimes considered for persistent or relapsing infection in highly immunocompromised patients. Not routine first-line treatment. [1,2] |
| 5 | Atovaquone + clindamycin | An alternative combination reported in selected refractory cases. Evidence is much more limited than for standard first-line therapy. [1,2] |
| 6 | Atovaquone/proguanil + azithromycin | Has been used in selected relapsing or difficult-to-treat cases. Clinical evidence is limited; specialist oversight is necessary. [1,2] |
| 7 | Red-blood-cell exchange transfusion | Removes infected erythrocytes while replacing them with donor cells. Considered in selected severe cases, including high parasitemia or substantial hemolysis and pulmonary, renal, or hepatic compromise. It supplements rather than replaces antimicrobial treatment. [1,2] |
| 8 | Supportive treatment for hemolysis and organ failure | Depending on the presentation, this may include transfusion for clinically significant anemia, oxygen or ventilatory support, renal replacement therapy, and hemodynamic support. These measures treat complications, not the parasite directly. [1,2] |
| 9 | Mefloquine | Can be effective and we have not seen psychiatric side effects. |
| 10 | Arakoda (tafenoquine) | Long-acting, superior medicine we published on in 2006. |
| 11 | Primaquine | Quite useful. |
The IDSA guideline supports atovaquone plus azithromycin as the preferred regimen and clindamycin plus quinine as the alternative. For highly immunocompromised patients, treatment may require at least six consecutive weeks, including the final two weeks with negative blood smears. Duration must be individualized to the clinical situation. [1,2].
We often treat residual Babesia with two teaspoons a day of “yellow paint” atovaquone both am and pm. And the most clear effective azithromycin dose was 2,000 mg/day. See my 2009 Babesia Update.
2. Herbs and Natural Compounds With Antibabesial Research
These are research candidates, not proven substitutes for prescription treatment. The most relevant paper below evaluated activity against B. duncani in a laboratory model; its results do not establish effective or safe human doses.
Cryptolepis sanguinolenta
In vitro evidence
A botanical extract and its alkaloid cryptolepine inhibited B. duncani in a laboratory erythrocyte model. Some exposed parasites did not regrow under the reported subculture conditions. Human efficacy and safety for babesiosis remain unestablished. [3]
10. Artemisia annua
Experimental
Sweet wormwood extracts showed inhibitory activity against B. duncani in vitro. Whole-herb preparations vary in composition and should not be assumed equivalent to standardized artemisinin medicines. [3]
11. Artemisia herba-alba
Animal and laboratory evidence
Extracts inhibited several piroplasm species in vitro. A mouse study also reported enhanced activity against B. microti when the extract was combined with diminazene. Diminazene is not a standard human babesiosis treatment, so this finding is not a clinical regimen. [4]
12. Scutellaria baicalensis
In vitro evidence
Chinese skullcap was among the botanical medicines reported to inhibit B. duncani in vitro. Baicalein, one of its studied constituents, also showed activity. This does not demonstrate that oral supplements achieve antiparasitic concentrations in patients. [3]
13. Polygonum cuspidatum
In vitro evidence
Japanese knotweed was included among botanical medicines with activity against B. duncani. Resveratrol and other constituents should not automatically be considered responsible for the observed whole-extract effect without compound-specific evidence. [3]
14. Alchornea cordifolia
In vitro evidence
This botanical extract also demonstrated inhibitory activity against B. duncani in the published laboratory model. Human pharmacokinetics, toxicity, dosing, and clinical effectiveness have not been established. [3]
3. Additional Synthetic or Experimental Antiparasitic Compounds
| # | Treatment | Evidence and Limitation |
|---|---|---|
| 15 | Artemisinin | Demonstrated in-vitro activity against B. duncani. This is not proof that an artemisinin monotherapy regimen clears human babesiosis. [3] We found very little human body effectiveness. |
| 16 | Artesunate | Demonstrated in-vitro antibabesial activity in the B. duncani model. Human babesiosis treatment efficacy is not established. [3] Wrong. We established this as effective 20 years ago. |
| 17 | Artemether | Showed activity against B. duncani in vitro. The study’s regrowth results are encouraging for research but do not validate clinical use. [3] Mixed reports. It is in Coartem. |
| 18 | Baicalein | A constituent studied in the B. duncani model, with reported in-vitro activity. Human dosing, safety, and efficacy against babesiosis remain unresolved. [3] |
| 19 | Berberine | Identified among compounds inhibiting B. bovis in a screening study. Activity against a veterinary Babesia species is not proof of efficacy against human B. microti or B. duncani. [5] |
| 20 | Other screened natural-product leads | Compounds including narasin and lasalocid showed activity against B. bovis in research. Their toxicity, veterinary origins, and lack of validated human treatment regimens make them drug-discovery leads rather than clinical options. [5] |
Research interpretation: The botanical and compound studies are useful for selecting candidates for further testing, including combination and resistance studies. They do not establish which products can safely eradicate parasites from human blood. Herbal extracts may also interact with prescription medicines or cause hepatic, renal, or hematologic toxicity.
4. HBOT, SOT, EBOO, and Other Adjunctive Approaches
These are included because you specifically requested them. Their inclusion does not mean they are proven treatments for Babesia.
21. Hyperbaric Oxygen Therapy (HBOT)
Proposed rationale: Raises dissolved oxygen in plasma and may improve oxygen delivery in selected conditions.
Evidence assessment: No established clinical evidence that HBOT eradicates human Babesia infection or improves parasite clearance. It must not delay treatment of anemia, hypoxemia, or shock.
22. Supportive Oligonucleotide Therapy (SOT)
Proposed rationale: Marketed as a sequence-directed approach intended to target pathogen nucleic acids.
Evidence assessment: No established, high-quality human clinical evidence validating Babesia-directed SOT for parasite clearance, relapse prevention, or clinical recovery. Laboratory target binding alone would not prove efficacy.
23. EBOO (Extracorporeal Blood Oxygenation and Ozonation)
Proposed rationale: Exposes blood outside the body to an oxygen/ozone process, with claims involving microbial reduction or oxidative effects.
Evidence assessment: Not an established treatment for babesiosis. There is no convincing clinical evidence that EBOO clears Babesia or improves outcomes. Extracorporeal handling and ozone exposure also introduce safety concerns. We did see drops in infected red blood cells.
24. Intravenous Immunoglobulin (IVIG)
Proposed rationale: Provides pooled antibodies and has immunomodulatory effects.
Evidence assessment: Not routine antiparasitic treatment. It may be considered for a separate, specific immune-mediated complication in selected cases, but evidence for treating Babesia itself is inadequate.
25. Immune-Status Optimization and Management of Immunosuppression
Proposed rationale: Identifies factors associated with persistent or relapsing infection and addresses reversible clinical contributors.
Evidence assessment: Particularly important in patients with B-cell depletion, hematologic malignancy, transplantation, or other major immune compromise. This is an individualized clinical strategy, not a stand-alone parasite-killing treatment. [1,2]
For HBOT, SOT, and EBOO, the central research question is not simply whether the procedure changes oxygen levels, oxidative markers, or pathogen nucleic acids. It is whether a controlled human study demonstrates a meaningful improvement in parasitemia, sustained clearance, relapse rates, organ outcomes, or survival. I could not identify established clinical evidence supporting those outcomes for these three interventions in human babesiosis.
Full References
References 1–2: Standard Treatment, Exchange Transfusion, and Refractory Infection
1. Krause PJ, Auwaerter PG, Bannuru RR, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA): 2020 Guideline on Diagnosis and Management of Babesiosis. Clinical Infectious Diseases. 2021;72(2):e49–e64. doi: 10.1093/cid/ciaa1216 (opens in new tab).
- Supports treatments 1–8 and 25.
- Covers diagnosis, standard antimicrobial combinations, exchange transfusion, and management of immunocompromised patients.
2. Centers for Disease Control and Prevention. Clinical Care of Babesiosis. Updated February 13, 2024. CDC Clinical Guidance (opens in new tab).
- Supports treatments 1–8 and 25.
- Provides clinical treatment regimens, monitoring considerations, and guidance for severe and relapsing infection.
References 3–4: Botanical and Artemisinin Research
3. Lawres LA, Garg A, Kumar V, et al. Botanical Medicines Cryptolepis sanguinolenta, Artemisia annua, Scutellaria baicalensis, Polygonum cuspidatum, and Alchornea cordifolia Demonstrate Inhibitory Activity Against Babesia duncani. Pathogens. 2021;10(3):281. doi: 10.3390/pathogens10030281 (opens in new tab).
- Supports treatments 9, 10, 12–13, and 15–18.
- Reports in-vitro activity of botanical extracts and selected constituents against B. duncani.
4. Evaluation of the in vitro and in vivo inhibitory effects of Artemisia herba-alba against the growth of piroplasm parasites. Veterinary Parasitology. 2022. Full Article, PubMed Central (opens in new tab).
- Supports treatment 11.
- Examines several Babesia and Theileria species in laboratory experiments and mice.
Reference 5: Drug Discovery and Natural-Product Screening
5. Discovering the Potent Inhibitors Against Babesia bovis in vitro and Babesia microti in vivo by Repurposing the Natural Product Compounds. Frontiers in Veterinary Science. 2021;8:762107. doi: 10.3389/fvets.2021.762107 (opens in new tab).
- Supports treatments 19–20.
- Evaluates selected compounds against veterinary Babesia in vitro and B. microti in mice. The results are preliminary and do not establish safe human treatments.
Additional Source for Treatment 3
6. Centers for Disease Control and Prevention. Clinical Overview of Babesiosis. CDC Clinical Overview (opens in new tab).
– Provides diagnostic context, treatment considerations, and information about severe disease.
Practical Evidence Ranking
| Evidence Category | Treatments | Interpretation |
|---|---|---|
| Established clinical treatment | 1–3, 7–8 | Supported by clinical guidelines; selected treatment depends on severity and patient factors. |
| Specialist-directed refractory treatment | 4–6 | Limited evidence; requires individualized infectious-disease management. |
| Experimental botanicals and compounds | 9–20 | Laboratory or animal findings; not validated substitutes for human treatment. |
| Unproven adjunctive procedures | 21–24 | No established evidence of Babesia eradication or improved clinical outcomes. |
| Management of host risk factors | 25 | Important for persistent or relapsing disease, particularly in immunocompromised patients. |
One important research limitation: A list of 25 approaches should not be interpreted as 25 treatments with equivalent evidence. For a publication-quality review, I would keep human clinical evidence separate from veterinary studies, animal experiments, in-vitro findings, and procedures for which Babesia-specific clinical efficacy has not been established.